



Docket No.: 066782-0056

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of	:	Customer Number: 41552
Mazar, Andrew P., et al.	:	Confirmation Number: 8000
Application No.: 10/655,201	:	Group Art Unit: 1654
Filed: September 03, 2003	:	Examiner: C.R. Tate
For:	:	
ANTI-INVASIVE AND ANTI-ANGIOGENIC COMPOSITIONS AND METHODS		

TERMINAL DISCLAIMER AND CERTIFICATION
UNDER RULE 1.321 & 3.73(b)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Your Petitioner, Angstrom Pharmaceuticals, Inc., a corporation of the State of Delaware and having an office at 10655 Roselle Streete, Suite G, San Diego, California 92191, represents that it is the Assignee of the entire right, title and interest in and to U. S. Application No. 10/655,201, entitled ANTI-INVASIVE AND ANTI-ANGIOGENIC COMPOSITIONS AND METHODS filed on September 03, 2003, by virtue of the Assignment dated January 16, 1998 and recorded at Reel 008913, Frame 415, in serial number 08/900,327, filed July 25, 1997.

Your Petitioner further represents that it is the assignee of the entire right, title and interest in and to United States Patent No. 5,994,309, dated November 30, 1999, by virtue of the Assignment dated January 16, 1998 and recorded at Reel 008913, Frame 415, in serial number 08/900,327, filed July 25, 1997.

10/27/2004 AWONDAF1 00000028 502624 10655201

01 FC:1814 110.00 DA

No.: 10/655,201

Your Petitioner hereby disclaims the terminal part of any patent granted on said U. S. Application No. 10/655,201 which would extend beyond the expiration date of U. S. Patent No. 5,994,309 issued November 30, 1999.

Your Petitioner further agrees that any patent issuing on said U. S. Patent Application No. 10/655,201 shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to said U. S. Patent No. 5,994,309, this agreement to run with any patent granted on said U. S. Patent Application No. 10/655,201 and to be binding upon the grantee, its successor or assigns.

In making the above disclaimer, Petitioner does not disclaim any terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

No.: 10/655,201



CERTIFICATE UNDER 37 CFR 3.73(b)

Angstrom Pharmaceuticals, Inc. a corporation of the State of Delaware certifies that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of:

An Assignment from the inventor(s) of the patent application identified above. The assignment was recorded in the Patent and Trademark Office at Reel 008913, Frame 415.

The undersigned has reviewed all the documents in the chain of title of the patent application identified above and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

The undersigned further declares that all statements made herein of its own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Please charge the \$110.00 Disclaimer fee to Deposit Account Number 502624.

Respectfully submitted,

Date: 10-15-04

Name: Virgil Thompson

Title: President and Chief Executive Officer

Signature: Virgil Thompson